vs
Orthofix Medical Inc.（OFIX）与PEOPLES BANCORP INC（PEBO）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是PEOPLES BANCORP INC的1.9倍（$219.9M vs $118.7M），PEOPLES BANCORP INC净利率更高（24.4% vs -1.0%，领先25.5%），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs 3.7%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
该公司是总部位于美国明尼苏达州明尼阿波利斯、在特拉华州注册的美国跨国银行机构。截至2025年，它是美国第五大银行，同时也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构。它主营银行、投资、抵押贷款等相关金融业务。
OFIX vs PEBO — 直观对比
营收规模更大
OFIX
是对方的1.9倍
$118.7M
净利率更高
PEBO
高出25.5%
-1.0%
两年增速更快
OFIX
近两年复合增速
3.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $118.7M |
| 净利润 | $-2.2M | $29.0M |
| 毛利率 | 71.1% | — |
| 营业利润率 | 0.2% | — |
| 净利率 | -1.0% | 24.4% |
| 营收同比 | 2.0% | — |
| 净利润同比 | 92.4% | -8.7% |
| 每股收益（稀释后） | $-0.05 | $0.81 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXPEBO
| Q1 26 | — | $118.7M | ||
| Q4 25 | $219.9M | $117.3M | ||
| Q3 25 | $205.6M | $115.2M | ||
| Q2 25 | $203.1M | $114.5M | ||
| Q1 25 | $193.6M | $112.4M | ||
| Q4 24 | $215.7M | $111.6M | ||
| Q3 24 | $196.6M | $113.7M | ||
| Q2 24 | $198.6M | $110.3M |
净利润OFIXPEBO
| Q1 26 | — | $29.0M | ||
| Q4 25 | $-2.2M | $31.8M | ||
| Q3 25 | $-22.8M | $29.5M | ||
| Q2 25 | $-14.1M | $21.2M | ||
| Q1 25 | $-53.1M | $24.3M | ||
| Q4 24 | $-29.1M | $26.9M | ||
| Q3 24 | $-27.4M | $31.7M | ||
| Q2 24 | $-33.4M | $29.0M |
毛利率OFIXPEBO
| Q1 26 | — | — | ||
| Q4 25 | 71.1% | — | ||
| Q3 25 | 72.2% | — | ||
| Q2 25 | 68.7% | — | ||
| Q1 25 | 62.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 68.7% | — | ||
| Q2 24 | 67.8% | — |
营业利润率OFIXPEBO
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | 32.4% | ||
| Q3 25 | -8.3% | 33.0% | ||
| Q2 25 | -7.9% | 24.0% | ||
| Q1 25 | -25.2% | 27.9% | ||
| Q4 24 | -5.3% | 31.2% | ||
| Q3 24 | -9.6% | 36.0% | ||
| Q2 24 | -12.5% | 32.5% |
净利率OFIXPEBO
| Q1 26 | — | 24.4% | ||
| Q4 25 | -1.0% | 27.1% | ||
| Q3 25 | -11.1% | 25.6% | ||
| Q2 25 | -6.9% | 18.5% | ||
| Q1 25 | -27.4% | 21.7% | ||
| Q4 24 | -13.5% | 24.1% | ||
| Q3 24 | -13.9% | 27.9% | ||
| Q2 24 | -16.8% | 26.3% |
每股收益（稀释后）OFIXPEBO
| Q1 26 | — | $0.81 | ||
| Q4 25 | $-0.05 | $0.89 | ||
| Q3 25 | $-0.57 | $0.83 | ||
| Q2 25 | $-0.36 | $0.59 | ||
| Q1 25 | $-1.35 | $0.68 | ||
| Q4 24 | $-0.76 | $0.76 | ||
| Q3 24 | $-0.71 | $0.89 | ||
| Q2 24 | $-0.88 | $0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $82.9M |
| 总债务越低越好 | — | $691.3M |
| 股东权益账面价值 | $450.0M | $1.2B |
| 总资产 | $850.6M | $9.6B |
| 负债/权益比越低杠杆越低 | — | 0.57× |
8季度趋势，按日历期对齐
现金及短期投资OFIXPEBO
| Q1 26 | — | $82.9M | ||
| Q4 25 | $82.0M | $189.0M | ||
| Q3 25 | $62.9M | $190.2M | ||
| Q2 25 | $65.6M | $186.1M | ||
| Q1 25 | $58.0M | $187.0M | ||
| Q4 24 | $83.2M | $217.7M | ||
| Q3 24 | $30.1M | $283.7M | ||
| Q2 24 | $26.4M | $235.9M |
总债务OFIXPEBO
| Q1 26 | — | $691.3M | ||
| Q4 25 | — | $204.1M | ||
| Q3 25 | $157.2M | $227.3M | ||
| Q2 25 | $157.0M | $232.4M | ||
| Q1 25 | $156.9M | $237.0M | ||
| Q4 24 | $157.0M | $238.1M | ||
| Q3 24 | $118.5M | $236.8M | ||
| Q2 24 | $118.0M | $234.3M |
股东权益OFIXPEBO
| Q1 26 | — | $1.2B | ||
| Q4 25 | $450.0M | $1.2B | ||
| Q3 25 | $442.5M | $1.2B | ||
| Q2 25 | $458.3M | $1.2B | ||
| Q1 25 | $458.3M | $1.1B | ||
| Q4 24 | $503.1M | $1.1B | ||
| Q3 24 | $525.9M | $1.1B | ||
| Q2 24 | $546.0M | $1.1B |
总资产OFIXPEBO
| Q1 26 | — | $9.6B | ||
| Q4 25 | $850.6M | $9.6B | ||
| Q3 25 | $832.6M | $9.6B | ||
| Q2 25 | $837.2M | $9.5B | ||
| Q1 25 | $823.1M | $9.2B | ||
| Q4 24 | $893.3M | $9.3B | ||
| Q3 24 | $867.9M | $9.1B | ||
| Q2 24 | $882.0M | $9.2B |
负债/权益比OFIXPEBO
| Q1 26 | — | 0.57× | ||
| Q4 25 | — | 0.17× | ||
| Q3 25 | 0.36× | 0.19× | ||
| Q2 25 | 0.34× | 0.20× | ||
| Q1 25 | 0.34× | 0.21× | ||
| Q4 24 | 0.31× | 0.21× | ||
| Q3 24 | 0.23× | 0.21× | ||
| Q2 24 | 0.22× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | — |
| 自由现金流经营现金流 - 资本支出 | $16.8M | — |
| 自由现金流率自由现金流/营收 | 7.6% | — |
| 资本支出强度资本支出/营收 | 4.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.3M | — |
8季度趋势，按日历期对齐
经营现金流OFIXPEBO
| Q1 26 | — | — | ||
| Q4 25 | $27.7M | $134.7M | ||
| Q3 25 | $12.4M | $14.4M | ||
| Q2 25 | $11.6M | $50.7M | ||
| Q1 25 | $-18.4M | $34.3M | ||
| Q4 24 | $23.7M | $143.2M | ||
| Q3 24 | $11.7M | $34.1M | ||
| Q2 24 | $9.0M | $32.1M |
自由现金流OFIXPEBO
| Q1 26 | — | — | ||
| Q4 25 | $16.8M | $128.7M | ||
| Q3 25 | $2.5M | $12.7M | ||
| Q2 25 | $4.5M | $49.2M | ||
| Q1 25 | $-25.1M | $31.5M | ||
| Q4 24 | $15.2M | $136.4M | ||
| Q3 24 | $6.3M | $33.2M | ||
| Q2 24 | $-360.0K | $30.2M |
自由现金流率OFIXPEBO
| Q1 26 | — | — | ||
| Q4 25 | 7.6% | 109.7% | ||
| Q3 25 | 1.2% | 11.0% | ||
| Q2 25 | 2.2% | 43.0% | ||
| Q1 25 | -13.0% | 28.1% | ||
| Q4 24 | 7.0% | 122.2% | ||
| Q3 24 | 3.2% | 29.2% | ||
| Q2 24 | -0.2% | 27.4% |
资本支出强度OFIXPEBO
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | 5.1% | ||
| Q3 25 | 4.8% | 1.5% | ||
| Q2 25 | 3.5% | 1.3% | ||
| Q1 25 | 3.5% | 2.4% | ||
| Q4 24 | 4.0% | 6.1% | ||
| Q3 24 | 2.7% | 0.8% | ||
| Q2 24 | 4.7% | 1.7% |
现金转化率OFIXPEBO
| Q1 26 | — | — | ||
| Q4 25 | — | 4.24× | ||
| Q3 25 | — | 0.49× | ||
| Q2 25 | — | 2.39× | ||
| Q1 25 | — | 1.41× | ||
| Q4 24 | — | 5.32× | ||
| Q3 24 | — | 1.08× | ||
| Q2 24 | — | 1.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
PEBO
| Net Interest Income | $90.4M | 76% |
| Noninterest Income | $28.3M | 24% |
